FDA approves first RSV vaccine for at-risk adults in their 50s
- The FDA expanded approval of GSK's RSV vaccine to adults aged 50 to 59 at risk of severe illness.
- Arexvy is the first vaccine FDA approved to protect this age group from RSV.
- Initially approved for ages 60 and above, GSK's jab's safety data in 50-59 group aligned with older adults.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left1Leaning Right2Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
11%
C 67%
R 22%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage